NTRA News and Press, Natera Inc. From 12/01/20

Largest U.S. Health Plan Now Covers Non-Invasive Prenatal Testing (NIPT) for all Pregnancies PR Newswire SAN CARLOS, Calif., Dec. 1, 2020 SAN CARLOS, Calif. , Dec. 1, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in...

Healthcare experienced a significant risk-diminishing event as the Affordable Care Act appears more secure. Biotechs continue to lead healthcare as vaccine progress and key approvals draw significant attention. Drug pricing remains a dormant issue for now although key moves last w...

New Publication from I-SPY 2 Trial Highlights Signatera's Ability to Predict Treatment Outcomes in Neoadjuvant Breast Cancer Patients Study published in Annals of Oncology validates Signatera™ for use in neoadjuvant treatment response monitoring PR Newswire SAN CA...

Small caps finally record a new high after two years and turn positive for the year. Vaccine progress is raising expectations of a more robust and durable economic recovery in 2021, driving a rotation into lagging segments and economically sensitive sectors. Small caps can witness...

Natera Appoints Dr. Monica Bertagnolli to its Board of Directors Former president and current board member of ASCO brings deep oncology expertise and leadership PR Newswire SAN CARLOS, Calif., Nov. 19, 2020 SAN CARLOS, Calif. , Nov. 19, 2020 /PRNewswire/ ...

Multiple companies are working on next-gen blood biopsies tech to detect cancer. The potential market size is big according to most estimates and analysts. Mergers and acquisitions seem to suggest that the era of liquid biopsies has arrived. The frontrunners highlighted in the...

Natera to Present at the Canaccord Genuity Virtual MedTech & Diagnostics Forum Natera to Present at the Canaccord Genuity Virtual MedTech & Diagnostics Forum PR Newswire SAN CARLOS, Calif., Nov. 12, 2020 SAN CARLOS, Calif. , Nov. 12, 2020 /PRNewsw...

Natera Presents New Data at the 2020 SITC Annual Meeting Highlighting Applications of Personalized ctDNA Testing in Immunotherapy Treatment Monitoring Clinical case studies demonstrate the performance of the Signatera™ test in cancer patients receiving immunotherapy P...

Natera, Inc. (NTRA) Q3 2020 Earnings Conference Call November 5, 2020 16:30 ET Company Participants Steve Chapman - Chief Executive Officer Michael Brophy - Chief Financial Officer Solomon Moshkevich - General Manager, Oncology Paul Billings - Chief Medical Officer Conference Call Participant...

The following slide deck was published by Natera, Inc. in conjunction with their 2020 Q3 earnings call. For further details see: Natera, Inc. 2020 Q3 - Results - Earnings Call Presentation